-+ 0.00%
-+ 0.00%
-+ 0.00%

Bausch + Lomb releases Phase 2 BL1107 glaucoma study update

PUBT·07/09/2026 20:31:28
Listen to the news
Bausch + Lomb releases Phase 2 BL1107 glaucoma study update
  • Bausch + Lomb released topline Phase 2 results for glaucoma candidate BL1107.
  • Trial missed the primary endpoint on visual field mean deviation at Day 28; key secondary visual function endpoints also missed.
  • Program will not advance in glaucoma as a topical eye drop; focus shifts to a sustained-release implant for geographic atrophy, with trials expected in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260709686233) on July 09, 2026, and is solely responsible for the information contained therein.